Loading
A phase 2 trial of Datopotamab deruxtecan, Capecitabine, Fluorouracil in endometrial cancer and prostate cancer, run by AstraZeneca, now recruiting.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03). ClinicalTrials.gov record last updated 2026-09-23: recruiting. Enrollment is planned at 454 participants. Primary completion is estimated at 2027-10-01. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin. Registered primary measures: Objective response rate (ORR); The number of subjects with adverse events/serious adverse events; PSA50 response (Substudy 3 only).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, Datopotamab deruxtecan, T-cell exhaustion and CAR-T persistence, TROP2.
Shares Rilvegostomig, Datopotamab deruxtecan, T-cell exhaustion and CAR-T persistence, TROP2.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer.
Shares Rilvegostomig, Datopotamab deruxtecan, T-cell exhaustion and CAR-T persistence, AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/